<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376646</url>
  </required_header>
  <id_info>
    <org_study_id>CL-VP-02</org_study_id>
    <nct_id>NCT03376646</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of Dissolve™ Compared to Resolute™ Integrity in Treatment of Coronary Small Vessel Disease in Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DK Medical Technology (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Core Medical (Beijing) Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DK Medical Technology (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety in the treatment of Coronary
      Small Vessel Disease by drug coated balloon (DCB) Dissolve™ versus drug eluting stent (DES)
      Resolute™ Integrity.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment percent diameter stenosis of the target lesion at 9 months after procedure</measure>
    <time_frame>9 months after the procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success rate of the interventional therapy</measure>
    <time_frame>From the start of index procedure to the end of index procedure, Day 0</time_frame>
    <description>Successful delivery and use of the assigned balloon/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final residual stenosis of less than 50% and TIMI 3 blood flow (DCB arm) or less than 30% and TIMI 3 blood flow (DES arm) by visual estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success rate of the interventional therapy</measure>
    <time_frame>From the start of index procedure to the end of index procedure, Day 0</time_frame>
    <description>Attainment of final residual stenosis of less than 50% and TIMI 3 blood flow (DCB arm) or less than 30% and TIMI 3 blood flow (DES arm) by visual estimation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate of the interventional therapy</measure>
    <time_frame>7 days after the procedure</time_frame>
    <description>Without the occurrence of cardiac death, target vessel Myocardial Infarction (MI) or repeat target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-device percent diameter stenosis of the target lesion</measure>
    <time_frame>9 months after the procedure</time_frame>
    <description>Restenosis is defined as stenosis &gt; 50% by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-device minimal lumen diameter (MLD)</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment MLD</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-device late lumen loss (LLL)</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment LLL</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate in lesion section</measure>
    <time_frame>9 months after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all adverse events and severe adverse events</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major adverse cardiovascular events</measure>
    <time_frame>1 month, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure</time_frame>
    <description>Including death, myocardial infarction (MI), stroke and renal failure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>Coronary Small Vessel Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A: Dissolve™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: Resolute™ Integrity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Dissolve™-2.00mm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B is single arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cohort A: Dissolve™</intervention_name>
    <description>Dissolve™ are to be used in the trial</description>
    <arm_group_label>Cohort A: Dissolve™</arm_group_label>
    <other_name>Paclitaxel coated balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cohort A: Resolute™ Integrity</intervention_name>
    <description>Resolute™ Integrity are to be used in the trial</description>
    <arm_group_label>Cohort A: Resolute™ Integrity</arm_group_label>
    <other_name>Zotarolimus eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cohort B: Dissolve™-2.00mm</intervention_name>
    <description>Dissolve™ are to be used in the trial</description>
    <arm_group_label>Cohort B: Dissolve™-2.00mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Related to the patients:

        Cohort A:

          1. Patients who agree to accept the angiography follow-up visit at 9-month and follow up
             visits at 1-month, 6-month, 9-month, 1-year, 2-year, 3-year, 4-year and 5-year

          2. Patients with stable angina, unstable angina, old myocardial infarction (including ST
             elevation MI or Non-ST elevation MI) or proven asymptomatic ischemia

          3. Patients who can receive any kind of coronary revascularization (including balloon
             angioplasty, stent implantation or coronary artery bypass grafting)

             Cohort B: All candidates for Cohort B of this study must meet number 1, 2 of the above
             criteria and

          4. Patients who can receive balloon angioplasty

             Related to lesion:

             Cohort A

          5. The reference blood vessel diameter is 2.25 mm-2.75 mm, length ≤ 26mm

          6. Before surgery, stenosis diameter must be ≥ 70% or ≥ 50% and accompanied by ischemia

          7. One subject is allowed to have 1 target lesion at most (Two lesions can be treat as
             one target lesion, if they are in the same vessel, with the distance less than 10mm,
             with total length ≤ 26mm, and can be intervened by one DCB or DES)

             Cohort B: All candidates for Cohort B of this study must meet number 6,7 of the above
             criteria and

          8. The reference blood vessel diameter is 2.00mm-2.25mm

        Exclusion Criteria:

        Related to patients

          1. Patients who had Myocardial Infarction within 1 week before being included

          2. Patients with severe congestive heart failure or NYHA grade IV heart failure

          3. Left ventricular ejection fraction (LVEF) &lt; 35%

          4. Patients who had heart transplantation

          5. Patients with severe valvular heart disease

          6. The patients had cerebral stroke within 6 months before being included, or have a
             history of peptic ulcer or gastrointestinal bleeding, or the patients have a bleeding
             tendency according to the investigator

          7. Patients with leukopenia (white blood cell count &lt; 3×10^9/L) for more than three days;
             Patients with low neutrophil counts (ANC &lt; 1000/mm^3) for more than three days;
             Patients with thrombocytopenia (platelet count &lt; 100,000/mm^3)

          8. Patients with renal insufficiency (eGFR &lt; 30mL/min)

          9. Patients who are forbidden to use anticoagulation agents or anti-platelet drugs, and
             unable to tolerate Aspirin or Clopidogrel

         10. Patients who are allergic to Paclitaxel or Zotarolimus

         11. The patients have a life expectancy of less than 12 months, or it would be difficult
             to finish follow-ups within 12 months

         12. Pregnant or lactating women, or women who plan to get pregnant within 12 months or
             refuse to take effective contraceptives

         13. The patients are participating in any other clinical trials before reaching the
             primary endpoints

         14. Patients who are unsuitable for the study according to the investigator due to other
             reasons

             Related to the Lesion:

         15. Patients with total occlusion at the target lesion

         16. Patients who have severe calcification of the target lesion, and balloon
             pre-dilatation could not be performed successfully

         17. The target lesions are bifurcation lesion with the diameter of the branch vessel &gt;
             2.00mm

         18. The target lesions are in-stent restenosis

         19. Angiography indicates thrombosis in the target vessel

         20. Complicated with lesions in left main (LM) coronary requiring intervention treatment

         21. More than 2 non-target lesions need treatment, or the non-target lesion could not be
             intervened successfully before the target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shubin Qiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shubin Qiao</last_name>
    <phone>86(010)88398866</phone>
    <email>qsbfw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yujie Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fucheng Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shubin Qiao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhujun Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weimin Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mao Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuchen Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Qu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Daqing Oil Field</name>
      <address>
        <city>Daqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guosheng Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiutang Zeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaobin Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunguang Qiu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>April 8, 2018</last_update_submitted>
  <last_update_submitted_qc>April 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

